Shu Y - Search Results

1

Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment.

Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, Zhang H. Xu X, et al. Among authors: shu y. Adv Drug Deliv Rev. 2021 Sep;176:113891. doi: 10.1016/j.addr.2021.113891. Epub 2021 Jul 26. Adv Drug Deliv Rev. 2021. PMID: 34324887 Free article. Review.

2

Assessment of cervical lymph node metastases using indirect computed tomography lymphography with iopamidol in a tongue VX2 carcinoma model.

Shu Y, Xu X, Wang Z, Dai W, Zhang Y, Yu Y, Sha Y, Wu H. Shu Y, et al. J Laryngol Otol. 2011 Aug;125(8):820-8. doi: 10.1017/S0022215111000958. Epub 2011 May 31. J Laryngol Otol. 2011. PMID: 21729450

3

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.

Gao X, Tao Y, Lamas V, Huang M, Yeh WH, Pan B, Hu YJ, Hu JH, Thompson DB, Shu Y, Li Y, Wang H, Yang S, Xu Q, Polley DB, Liberman MC, Kong WJ, Holt JR, Chen ZY, Liu DR. Gao X, et al. Among authors: shu y. Nature. 2018 Jan 11;553(7687):217-221. doi: 10.1038/nature25164. Epub 2017 Dec 20. Nature. 2018. PMID: 29258297 Free PMC article.

4

Direct Functional Protein Delivery with a Peptide into Neonatal and Adult Mammalian Inner Ear In Vivo.

Zhang K, Cheng X, Zhao L, Huang M, Tao Y, Zhang H, Rosenholm JM, Zhuang M, Chen ZY, Chen B, Shu Y. Zhang K, et al. Among authors: shu y. Mol Ther Methods Clin Dev. 2020 Jun 30;18:511-519. doi: 10.1016/j.omtm.2020.06.023. eCollection 2020 Sep 11. Mol Ther Methods Clin Dev. 2020. PMID: 32953927 Free PMC article.

5

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice.

Gu X, Hu X, Wang D, Xu Z, Wang F, Li D, Li GL, Yang H, Li H, Zuo E, Shu Y. Gu X, et al. Among authors: shu y. Cell Res. 2022 Jul;32(7):699-702. doi: 10.1038/s41422-022-00624-y. Epub 2022 Feb 23. Cell Res. 2022. PMID: 35197607 Free PMC article. No abstract available.

6

Structural insights into Cas9 mismatch: promising for development of high-fidelity Cas9 variants.

Tang H, Wang D, Shu Y. Tang H, et al. Among authors: shu y. Signal Transduct Target Ther. 2022 Aug 4;7(1):271. doi: 10.1038/s41392-022-01139-z. Signal Transduct Target Ther. 2022. PMID: 35927241 Free PMC article. No abstract available.

7

Microfluidic-assisted biomineralization of CRISPR/Cas9 in near-infrared responsive metal-organic frameworks for programmable gene-editing.

Xu X, Liu C, Wang S, Mäkilä E, Wang J, Koivisto O, Zhou J, Rosenholm JM, Shu Y, Zhang H. Xu X, et al. Among authors: shu y. Nanoscale. 2022 Nov 3;14(42):15832-15844. doi: 10.1039/d2nr04095f. Nanoscale. 2022. PMID: 36255392 Free article.

8

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.

Tao Y, Lamas V, Du W, Zhu W, Li Y, Whittaker MN, Zuris JA, Thompson DB, Rameshbabu AP, Shu Y, Gao X, Hu JH, Pei C, Kong WJ, Liu X, Wu H, Kleinstiver BP, Liu DR, Chen ZY. Tao Y, et al. Among authors: shu y. Nat Commun. 2023 Aug 15;14(1):4928. doi: 10.1038/s41467-023-40476-7. Nat Commun. 2023. PMID: 37582836 Free PMC article.

9

The application of genome editing in studying hearing loss.

Zou B, Mittal R, Grati M, Lu Z, Shu Y, Tao Y, Feng Y, Xie D, Kong W, Yang S, Chen ZY, Liu X. Zou B, et al. Among authors: shu y. Hear Res. 2015 Sep;327:102-8. doi: 10.1016/j.heares.2015.04.016. Epub 2015 May 15. Hear Res. 2015. PMID: 25987504 Free PMC article. Review.

10

Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing.

Gu X, Wang D, Xu Z, Wang J, Guo L, Chai R, Li G, Shu Y, Li H. Gu X, et al. Among authors: shu y. Genome Biol. 2021 Mar 22;22(1):86. doi: 10.1186/s13059-021-02311-4. Genome Biol. 2021. PMID: 33752742 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,614 results

Search Page